COGT

Cogent Biosciences (COGT)

Cogent Biosciences Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:COGT

1 2 3 4 5 6 7 8 9 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/12/10	06 : 01	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:COGT	Cogent Biosciences Inc
2024/12/09	21 : 00	GlobeNewswire Inc.	Cogent Biosciences Announces Updated Clinical Results from SUMMIT, Showcasing Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients	NASDAQ:COGT	Cogent Biosciences Inc
2024/12/09	02 : 00	GlobeNewswire Inc.	Cogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)	NASDAQ:COGT	Cogent Biosciences Inc
2024/11/15	06 : 05	Edgar (US Regulatory)	Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]	NASDAQ:COGT	Cogent Biosciences Inc
2024/11/15	02 : 24	Edgar (US Regulatory)	Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]	NASDAQ:COGT	Cogent Biosciences Inc
2024/11/12	22 : 00	GlobeNewswire Inc.	Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2024 Financial Results	NASDAQ:COGT	Cogent Biosciences Inc
2024/11/05	23 : 00	GlobeNewswire Inc.	Cogent Biosciences Announces Bezuclastinib Presentations at the 66th Annual American Society of Hematology (ASH) Meeting	NASDAQ:COGT	Cogent Biosciences Inc
2024/10/23	20 : 00	GlobeNewswire Inc.	Cogent Biosciences Announces Pipeline Expansion into KRAS and Poster Presentations at the 2024 EORTC-NCI-AACR International Symposium on Molecular Targets and Cancer Therapeutics	NASDAQ:COGT	Cogent Biosciences Inc
2024/09/03	21 : 15	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:COGT	Cogent Biosciences Inc
2024/09/03	21 : 00	GlobeNewswire Inc.	Cogent Biosciences Announces Phase 3 PEAK Trial in Patients with Gastrointestinal Stromal Tumors (GIST) Has Completed Enrollment and Advanced Past Interim Futility Analysis	NASDAQ:COGT	Cogent Biosciences Inc
2024/08/07	05 : 53	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:COGT	Cogent Biosciences Inc
2024/08/06	21 : 40	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:COGT	Cogent Biosciences Inc
2024/08/06	21 : 20	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:COGT	Cogent Biosciences Inc
2024/08/06	21 : 00	GlobeNewswire Inc.	Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2024 Financial Results	NASDAQ:COGT	Cogent Biosciences Inc
2024/06/27	21 : 00	GlobeNewswire Inc.	Cogent Biosciences Announces Positive FDA Meeting and Alignment on MS2D2, a Novel Patient Reported Outcome Measure for the SUMMIT trial	NASDAQ:COGT	Cogent Biosciences Inc
2024/06/14	20 : 30	GlobeNewswire Inc.	Cogent Biosciences Announces Additional Clinical Data from Part 1 of its Ongoing SUMMIT Trial Evaluating Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)	NASDAQ:COGT	Cogent Biosciences Inc
2024/06/14	08 : 18	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:COGT	Cogent Biosciences Inc
2024/06/14	08 : 14	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:COGT	Cogent Biosciences Inc
2024/06/14	08 : 11	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:COGT	Cogent Biosciences Inc
2024/06/14	08 : 07	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:COGT	Cogent Biosciences Inc
2024/06/13	19 : 06	Edgar (US Regulatory)	Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]	NASDAQ:COGT	Cogent Biosciences Inc
2024/06/13	10 : 01	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:COGT	Cogent Biosciences Inc
2024/06/06	05 : 02	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:COGT	Cogent Biosciences Inc
2024/05/30	05 : 03	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:COGT	Cogent Biosciences Inc
2024/05/30	05 : 01	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:COGT	Cogent Biosciences Inc
2024/05/24	06 : 05	GlobeNewswire Inc.	Cogent Biosciences Appoints Cole Pinnow as Chief Commercial Officer	NASDAQ:COGT	Cogent Biosciences Inc
2024/05/24	06 : 01	GlobeNewswire Inc.	Cogent Biosciences Announces Positive Updated Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST) at ASCO Annual Meeting	NASDAQ:COGT	Cogent Biosciences Inc
2024/05/07	21 : 26	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:COGT	Cogent Biosciences Inc
2024/05/07	21 : 19	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:COGT	Cogent Biosciences Inc
2024/05/07	21 : 00	GlobeNewswire Inc.	Cogent Biosciences Reports First Quarter 2024 Financial Results	NASDAQ:COGT	Cogent Biosciences Inc